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Abstract: Preterm birth is the leading cause of neonatal mortality and morbidity and long-term 
disability of non-anomalous infants. Previous studies have identiﬁ  ed a prior early spontaneous 
preterm birth as the risk factor with the highest predictive value for recurrence. Two recent 
double blind randomized placebo controlled trials reported lower preterm birth rate with 
the use of either intramuscular 17 alpha-hydroxyprogesterone caproate (IM 17OHP-C) or 
intravaginal micronized progesterone suppositories in women at risk for preterm delivery. 
However, it is still unclear which high-risk women would truly beneﬁ  t from this treatment in a 
general clinical setting and whether socio-cultural, racial and genetic differences play a role in 
patient’s response to supplemental progesterone. In addition the patient’s acceptance of such 
recommendation is also in question. More research is still required on identiﬁ  cation of at risk 
group, the optimal gestational age at initiation, mode of administration, dose of progesterone 
and long-term safety.
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Introduction to management and issues 
of preterm birth
Premature delivery, deﬁ  ned as birth prior to 37 weeks, remains one of the major 
problems that lead to perinatal morbidity and mortality in the developed countries.1 
It affects approximately 12.5% of all deliveries in the US; one third of these occur 
before 34 weeks’ gestation.2,3 These numbers reﬂ  ect an increase of 30% over the 
preterm birth (PTB) rate reported in 19813 and equates to nearly 500,000 PTBs 
each year. This prematurity rate has been increasing probably as a result of delayed 
child bearing and to the increased frequency of multifetal pregnancies from assisted 
reproductive technology.4,5 The rate of PTB is substantially higher in African American 
and Hispanics as compared to Caucasians.6,7
Prematurity causes an estimated 70% of all neonatal deaths of non-anomalous 
infants in the United States.8 Neonatal mortality is directly correlated with gestational 
age (GA) at delivery. The mortality rate for infants born at less than 32 weeks’ gestation 
is almost 70 times the rate of a term infant,9 and for infants born less than 37 weeks’ 
gestation it is 15 times the term infant rate (2.6/1000 live births). Reported neonatal 
morbidity is also a major concern, especially for infants born at less than 32 weeks’ 
gestation. Neonatal complications include intraventricular hemorrhage, necrotizing 
enterocolitis, respiratory distress syndrome, bronchopulmonary dysplasia, jaundice 
and anemia.3 Economically, care for these infants is responsible for an estimated 
US$51,600 investment per child in neonatal care, contributing more than US$26 billion 
to annual healthcare costs in the US.3 Among the infants who survive, 10%–15% 
are burdened with signiﬁ  cant handicaps, such as cerebral palsy, mental retardation, 
retinopathy, or hearing impairment.10 More importantly, low birth weight infants who Therapeutics and Clinical Risk Management 2009:5 56
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are spared signiﬁ  cant neonatal morbidity are at higher risk 
for cardiovascular disease (myocardial infarction, stroke, and 
hypertension) and diabetes as adults.10
Preterm delivery (PTD) is due to either spontaneous 
preterm labor (PTL) (40%–50%), spontaneous preterm 
premature rupture of membranes (PPROM) (25%–40%), 
or obstetrically indicated PTD (20%–25%) as a result of 
maternal, placental or fetal complications (preeclampsia, 
renal disease, diabetes mellitus with vasculopathy, placenta 
previa or abruptio, and fetal growth restriction).11
Risks factors for spontaneous PTD have been reported 
by members of the NICHD maternal-Fetal Medicine units 
network among 2929 pregnant women enrolled in the 
preterm prediction observational study.12 Risks factors 
analyzed included maternal demographics, previous history 
of PTD, presence or absence of fetal ﬁ  bronectin, bacterial 
vaginosis or shortened cervical length by ultrasound.13–16 
In addition, members of the above group also reported the use 
of antibiotics versus placebo in treating bacterial vaginosis 
or trichomonas, or upper genital infection (positive fetal 
ﬁ  bronectin) in the prevention of PTD. The results of these 
trials revealed no differences in PTD rates with the use of 
antibiotics.17,18
There are numerous studies suggesting a strong association 
between the presence of a short cervix in the mid-trimester 
and subsequent PTD at  37 weeks and  35 weeks’ 
gestation.14,19–21 In response to these studies, several authors 
recommended or reported on the use of cerclage for preven-
tion of PTB in women with shortened cervix. The results of 
these studies did not conclusively show cerclage to be efﬁ  ca-
cious.22–25 There are several protocols and regimens to treat 
women with PTL. Many of these include bed rest, and the use 
of tocolytics agents such as magnesium sulfate, betamimetics, 
or indomethacin. The results of these studies reveal a beneﬁ  -
cial effect in prolonging gestation for 48 hours, but without 
reduction in PTD rates.26–29
The role of socioeconomic status 
and ethnic origin and PTD
Social disadvantage whether deﬁ  ned by occupation, income, 
or degree of education, is associated with an increased risk 
of PTD.30–33 The reasons for this trend are not clear, but pos-
sible explanations include worse nutritional status, increased 
frequency of cigarette smoking, greater use of recreational 
drugs such as cocaine, higher rates of fetal growth restric-
tion, poorer quality and quantity of antenatal care, higher 
frequency of genital tract infection, physically demanding 
work, and higher levels of adverse psychological factors. 
Attempts to understand rates of PTD in lower socioeconomic 
groups have not yet yielded beneﬁ  t in terms of providing 
clues to the cause of PTB in general.30 Furthermore, attempts 
at intervention by improvement of social support mechanisms 
in this population have neither resulted in a decrease in the 
rates of PTD nor in improvement in outcome by any perinatal 
measures.34,35
  The PTB rate for black women is almost twice that 
for white women of comparable age in the USA irrespective 
of socioeconomic status.36 This racial gap has slightly 
diminished during the past 10 years largely due to an increase 
in PTD rates for white infants;36 although PTB rates have 
increased by 3.6% in black women (from 15.5% in 1975 
to 16% in 1995), a rise of 22.3% in white women (6.9% to 
8.4%) has been reported over the same interval.37 In black 
primigravid women in USA, rates of PTD increased from 
1975 to 1990 and began to decline thereafter, whereas among 
white primigravid women, the rates rose between 1975 and 
1995.38 Why this difference exists is not clear, but since the 
preponderance of preterm deliveries in the black population 
arose in the idiopathic PTL group, it can not be explained by 
variation in socio-economic status and hence is suggestive 
of a biological variation.
The role of acculturation and birth 
outcomes
Acculturation is a process that involves several variables. 
These variables include family roles, gender roles, and 
socioeconomic variables. The degree to which one 
acculturates may affect their behavior. A change in behavior 
can have an effect on health outcomes. Recent efforts to 
understand differences between US and foreign-born women 
of the same ethnicity focus on difference in behavior and 
health insurance, both of which are related to more general 
differences in acculturation. There is, for instance, signiﬁ  -
cant variation in smoking, and illicit drug use by nativity. 
Pregnant Latinos in California are between ﬁ  ve and 10 times 
more likely to use illicit drugs if they were born within as 
compared to outside of US.39 A similar pattern has been 
observed among the general population of Latinos in US.40,41 
Moreover, the extent of drug use was directly correlated 
with the degree of acculturation as measured by English 
language usage.
Other explanations for the birth outcome advantage 
enjoyed by foreign-born women include a more supportive 
family structure. The proportion of births to unmarried 
women, a possible proxy for family cohesion, is generally 
higher among US, as compared to foreign-born Latinos.42–44 Therapeutics and Clinical Risk Management 2009:5 57
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More generally, researchers have suggested that Latin culture, 
as proxied by mother’s birthplace or English Language usage, 
is protective of immigrant health.45,46
Preterm birth prevention program
Most PTB prevention programs have attempted to identify 
women who are likely to deliver prematurely based on 
the presence of numerous risk factors,11,47–49 including low 
socioeconomic status, maternal age less than 18 or greater 
than 40 years, increasing parity, race, previous preterm labor 
and delivery, multiple gestation, uterine malformations, and 
bacterial vaginosis.50–53 The most important of these factors 
is a history of PTD,54–56 which may be inﬂ  uenced by genetic 
and environmental determinants.57 However, the intergenera-
tional predisposition to PTB has not been well established, 
with some investigators ﬁ  nding a signiﬁ  cant effect58–60 and 
others ﬁ  nding no effect.61
Familial and intergenerational 
inﬂ  uence of PTB
The genetic basis for spontaneous preterm labor and delivery 
is complex and undoubtedly cannot be explained by a single 
gene polymorphism. It has been estimated that there are 
approximately 200,000 single nucleotide polymorphisms 
within the coding regions of the human genes.62 In addition; 
there are many repetitive DNA elements of variable length 
in the human genome. Different polymorphisms may have 
an additive or synergistic effect on the risk for severity 
of the disease.63 Furthermore individual combinations of 
polymorphisms may up-or down-regulate each other.64 This 
may partially explain the reason that a certain polymorphism 
is associated with spontaneous PTB in one ethnic group, but 
not in a different ethnic group.
There is also strong evidence of familial or intergenerational 
inﬂ  uence on PTD. A study from Scotland65 found that sisters 
of women who had delivered preterm low birth weight 
infants were more likely to have a preterm infant than the 
sisters of women who had delivered term growth-retarded 
infants. A Norwegian study61 found no signiﬁ  cant association 
between mother and offspring preterm status. However, a US 
study showed an increased risk of PTB among women who 
themselves were born before 37 weeks’ gestation.66 A previous 
history of PTD is one of the most important risk factors for a 
subsequent PTD.67 It has also been shown that the risk of PTD 
increases substantially with the number of previous preterm 
infants. Bakketeig and coworkers68 showed that the risk of PTD 
(deﬁ  ned as  36 weeks in their study) was 14.3% if the ﬁ  rst 
birth was preterm and 28.1% for the third pregnancy if both 
prior births were preterm. The risk of recurrence did not appear 
to be affected by the presence of medical complications, the 
length of the inter-pregnancy interval, or fetal survival. Vatten 
et al69 reported that after adjustment for maternal age and educa-
tion, interval between births, and the decade of birth, the risk of 
adverse pregnancy outcomes was higher in the second birth for 
women who changed partners between the ﬁ  rst 2 births com-
pared with women who had the same partner for both births. 
The relative risk of PTB before 37 weeks of gestation was 2.0 
(95% CI 1.9–2.1), for low birth weigh of less than 2,500 g the 
relative risk was 2.5 (95% CI 2.3–2.6), and for infant mortality 
the relative risk was 1.8 (95% CI 1.6–2.1). Similarly, paternal 
inheritance has also been implicated, when studying a group 
of 128,239 women who had two consecutive births; Li et al70 
observed that changing partners resulted in a 33% reduction in 
the risk of spontaneous PTD in women whose ﬁ  rst pregnancy 
led to delivery before 34 weeks of gestation. In contrast, among 
women whose ﬁ  rst pregnancy resulted in birth after 36 weeks 
of gestation, changing partners led to a 16% increase in the 
risk of early PTD during the subsequent pregnancy. However, 
this association could not be conﬁ  rmed by a Danish study that 
involved 14,147 index fathers who had at least 1 child who was 
delivered before 37 weeks of gestation.71
In summary, the causes of PTL are multifactorial, 
complex, and poorly understood. As a result, there are 
no tests or assessment measures available that accurately 
predict PTB.
Review of pharmacology, mode 
of action of progesterone 
and in particular 17 OHP-C
Role of progesterone and initiation 
of labor
The role of progesterone in pregnancy is unclear; however, 
it is known that the effects of progesterone on the myome-
trium are 2-fold: it suppresses the action of estrogen by 
inhibiting the replacement of cytosolic estrogen receptors 
and it exerts a direct effect on the biosynthetic processes 
of the uterus through its own cellular receptor.72–74 Thus 
the contractile capacity is maintained under the inﬂ  uence 
of progesterone, as indicated by the development of tension 
in the electrically stimulated uterus of progesterone-treated 
rabbits or rats.
The ability of progesterone to maintain uterine quiescence 
during pregnancy has been shown in lower mammalian 
species.75,76 In these species, progesterone withdrawal 
is a necessary step in the events leading to parturition. Therapeutics and Clinical Risk Management 2009:5 58
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Administration of exogenous progesterone to ewe blocked 
this sequence of events after glucocorticoid infusion to the 
fetus and effectively prevented the progression to labor and 
delivery.77,78 In women, the role of progesterone withdrawal 
as a mechanism for parturition has been questioned because 
maternal, fetal, and amniotic ﬂ  uid concentrations of proges-
terone are sustained before the onset of labor and delivery.79,80 
Nevertheless, the progesterone withdrawal theory remains 
a leading hypothesis because no other mechanism for the 
onset of human parturition has been deﬁ  nitively established 
and because synthetic antiprogestins stimulate myometrial 
contractions81,82 whereas inhibitors of 3B-hydroxysteroid 
dehydrogenase, which lower systemic progesterone levels, 
induce labor and delivery in women83 and in monkeys.84 
There is also an associated increase in the expression of a 
range of “pro-labor” genes, which are normally repressed by 
the presence of progesterone.85
Several explanations for “functional” progesterone 
withdrawal have been proposed, such as loss of proges-
terone receptors or change in receptor isoform expression, 
binding of progesterone to a high afﬁ  nity protein and 
therefore a reduction in free active steroid,86–87 production 
of a local antiprogestin, sequestration of progesterone into 
lipoproteins or localization of the progesterone withdrawal 
to the avascular fetal membranes so that a decrease is 
not detected in the circulation.88 None of these hypoth-
eses has been proven, and so the questions remains, how 
does “functional withdrawal” of progesterone prior to 
human labor occur? Conversely, how does progesterone 
replacement stops labor?
Progestins are available in natural or synthetic formulations 
for oral, intramuscular (IM) or vaginal administration in the 
form of suppository or gel. Natural (micronized) progesterone 
is an exact duplicate of the progesterone produced in the 
corpus luteum and placenta. It is therefore more readily 
metabolized by the body and is associated with minimal side 
effects.89 The two natural progesterone include progesterone 
and 17-hydroxyprogesterone. The plasma concentration will 
depend on the dose and route of administration,90 eg, oral 
(3–6 ng/mL @100 mg and 30 ng/mL @ 200 mg), transdermal 
(3 ng/mL @ 45 mg), vaginal cream (19 ng/mL @ 300 mg) 
or gel (3.9 ng/mL @ 90 mg), vaginal (10–19 ng/mL @ 
100 mg, 17–34 ng/mL @ 400 mg) or rectal (15–52 ng/mL 
@ 100 mg) suppository, IM (40–50 ng/mL @ 100 mg) and 
sublingual (5 ng/mL @ 10 mg dose). The time to peak plasma 
concentration is longest with 90 mg vaginal gel @ 7 hours 
and shortest with 200 mg oral micronized progesterone @ 
0.8 hour. The vaginal suppository (100 mg and 400 mg) and 
100 mg rectal suppository is about 4 hours and the IM route 
(100 mg) takes about 2–8 hours.90
Synthetic progestins are progesterone derivatives and 
19 nortestosterone derivatives; its chemical structure is very 
similar to that of the natural progesterone. 17 alpha hydroxy-
progesterone caproate (17OHP-C) is a 17-hydroxyprogesterone 
derivative, it is the most commonly used synthetic progestin 
given intramuscularly to prevent PTB.89 It has been isolated 
from both adrenal glands and corpora lutea. The synthetic 
caproate ester is inactive when given by mouth but works as 
a long-acting progestin when administered intramuscularly. 
Pharmacokinetic studies have shown that once-weekly IM.
Administration of 17OHPC would provide continuous 
systemic serum levels of 17OHP-C. The half-life of 17OHP-C 
was estimated to be approximately 7.8 days.91 The route of 
administration plays an important role in the drug’s safety 
and efﬁ  cacy proﬁ  le. Oral progesterone has not been used for 
prevention of PTB because of its ﬁ  rst-pass hepatic metabo-
lism, lack of efﬁ  cacy data, high side-effect proﬁ  le, extreme 
variability in plasma concentrations. Transvaginal adminis-
tration of progesterone avoids ﬁ  rst-pass hepatic metabolism 
and is associated with rapid absorption, high bioavailability, 
and local endometrial effects.92 It has been shown to provide 
higher and more sustained progesterone concentrations and 
is the preferred route of administration in many cases.93–95 
Although this route offers no local pain and few side effects, 
it is associated with variable blood concentrations.93,95
Efﬁ  cacy studies
Earlier trials: prior to year 2003
Earlier small trials using 17OHP-C showed mixed results; 
4 trials reported beneﬁ  t,96–99 whereas 2 trials reported no 
beneﬁ  t100,101 in reducing the risk of PTD. A meta-analysis 
over a decade ago102 showed that progesterone was beneﬁ  cial 
in reducing PTL: odds ratio 0.43 (95% CI 0.20, 0.89); PTB: 
odds ratio 0.50 (95% CI 0.30, 0.85) and low birth weight 
( 2500 g): odds ratio 0.50 (95% CI 0.27, 0.80). Because 
of these encouraging results, several trials were designed 
and conducted to evaluate the potential beneﬁ  ts of various 
progesterone preparations in preventing PTB in women at 
high risk for this complication.
Recent trials: year 2003 till present
Two recent published double blind randomized placebo-
controlled trials on singleton gestation reported lower 
PTB rate with the use of either progesterone vaginal 
suppositories103 or intramuscular (IM) 17OHP-C104 in women 
at risk for PTD (Table 1). Since the publication of these two Therapeutics and Clinical Risk Management 2009:5 59
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double blind placebo controlled studies.103,104 The National 
Institute of Child Health and Development (NICHD), 
the American College of Obstetricians and Gynecologist 
(ACOG) and the March of Dime endorsed the prophylactic 
use of 17OHP-C in women with history of preterm deliveries, 
although both studies had several limitations. For example: 
in the da Fonseca et al study,103 the women were not started 
on non-bioadhesive progesterone vaginal suppository till 
late gestation, the mean GA at enrollment was 25.2 weeks 
in the placebo group and 26.5 weeks in the progesterone 
vaginal suppositories group. In addition, women who 
delivered preterm following preterm premature rupture of 
membranes were excluded. If these women were included in 
the analysis, the difference in PTB is no longer statistically 
signiﬁ  cant. In the Meis et al study,104 the women enrolled 
had high rates of PTD, with 54.9 % of the women who 
received the placebo injections delivering before 37 weeks 
of gestation. This high rate of PTD was most likely related 
to the history of previous preterm deliveries. The earlier in 
a pregnancy a PTD occurs, the greater the chance of PTD 
in a subsequent pregnancy. It should also be noted that the 
mean duration of gestation at the time of the qualifying 
delivery was 31 weeks, and a third of the women enrolled 
had had more than one previous PTD. These women were 
very high risk, strongly motivated and compliant. On the 
other hand, 17OHP-C may not be effective in women with 
a lower risk of PTD, and most preterm deliveries occur in 
women with no previous PTD. Therefore, the result of Meis 
et al study104 should be interpreted with caution and may 
not be generalizable to women with a lower risk of PTD. 
In addition, although 17-OHPC signiﬁ  cantly reduced the 
rate of PTD among the women who received it, the rate of 
PTD in this group remained very high at 36.3 %. Thus, the 
identiﬁ  cation of other causes of PTD and other methods of 
preventing it remains a pressing need. Another noteworthy 
point is that although the Meis et al study104 demonstrated 
a statistically signiﬁ  cant reduction in the primary endpoint 
of PTB prior to 37 weeks’ gestation, the reduction in PTBs 
prior to 35 weeks and prior to 32 weeks’ gestation which 
are better surrogates for signiﬁ  cant neonatal morbidity and 
mortality, were not statistically persuasive. In addition, 
the primary clinical trial did not demonstrate a signiﬁ  cant 
reduction in another secondary endpoint, a composite assess-
ment of infant mortality and morbidity. In a subsequent 
data analysis of the NICHD trial104evaluating the beneﬁ  t 
of 17OHP-C according to the GA of previous delivery, 
Table 1 Randomized double-blind placebo controlled trials of the efﬁ  cacy of progesterone for the prevention of PTB (years 2003–2007)
Authors (year) Progest agent/dose/
duration
GA @ initiation 
(week)
# of subjects % preterm deliveries
Progest Placebo Progest Placebo
Meis et al104 
(2003)
17 OHP-C, weekly 
IM 250 mg. up to 
36.9 wks
16–20.9 singleton 310 153a <37 wk: 36.3
<35 wk: 20.6
<32 wk: 11.4
54.9
30.7
19.6
da Fonseca et al103 
(2003)
Natural micronized 
vaginal non-bioadhesive 
progest. suppositories, 
100 mg daily, up to 
34 wks
24–34 singleton 72 70 <37 wk: 13.8
<34 wk: 2.8
28.5
18.6
O’Brien et al106 
(2007)
Natural micronized 
vaginal bioadhesive 
progest. gel, 90 mg 
daily, up to 36.9 wks
18–22.9 singleton 309 302 ≤37 wk: 41.7
≤35 wk: 22.7
≤32 wk: 10.0
≤28 wk: 3.2
40.7
26.5
11.3
3.0
de Fonseca et al108 
(2007)
Natural micronized
vaginal non-bioadhesive 
progest. capsule, 
200 mg daily up to 
33.9 wks
20–25 singleton 
(~90%) and twin
125 125b <34 wk: 9.2 34.4
Rouse et al107 
(2007)
17 OHP-C, weekly 
IM 250 mg, up to 
35 wks
16–20.9 twin 325 330 <37 wk: 69.5
<32 wk: 6.9
<27 wk: 8.0
70.3
14.5
6.1
aPlacebo used was castor oil.
bPlacebo used was safﬂ  ower oil.
Abbreviations: Progest, progesterone; 17 OHP-C: 17 alpha hydroxyprogesterone caproate.Therapeutics and Clinical Risk Management 2009:5 60
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Spong et al105 reported that progesterone did not signiﬁ  cantly 
improve the GA at delivery in women whose earliest previ-
ous delivery was at 34–35.9 weeks’ gestation. However, the 
recurrence of PTB was signiﬁ  cantly less for women treated 
with 17OHP-C with GA at the earliest previous spontaneous 
PTB 20–27.9 weeks (42% vs 63%) and 28–33.9 weeks (34% 
vs 56%). From their data, the authors concluded that for the 
women with earliest previous spontaneous PTB at 20–27.9 
weeks and 28–33.9 weeks, 4.7 and 4.6 women (respectively 
for each group) would need to be treated with 17OHP-C to 
prevent one PTB.
In a multinational double blind placebo controlled trial 
on the use of bioadhesive progesterone vaginal gel for the 
prevention of PTB in 611 women,106 the ﬁ  ndings revealed 
no signiﬁ  cant differences between the progesterone vaginal 
gel and placebo in the rate of PTB at  35 weeks’ gestation 
(Table 1). This is in contrast to the previously mentioned 
trial by da Fonseca et al.103 Recently, Rouse et al107 presented 
the NICHD network data on the use of 17OHP-C in the 
prevention of PTB in twins, the results showed that treatment 
with 17OHP-C did not reduce the rate of PTB in twins 
(Table 1). Potential limitations of Rouse107 trial are: 1) less 
than 10% of enrolled women had a history of prior PTB; 
and, 2) they use the same 17 OHPC dose (250 mg) in women 
with twin gestation, when their plasma volume is known to be 
20% greater than that in singleton gestation. More recently, 
da Fonseca et al108 published a randomized, double blind 
placebo-controlled trial of 250 women with a short cervix 
( 15 mm by transvaginal ultrasound). The frequency of 
spontaneous PTB at  34 weeks was signiﬁ  cantly lower in the 
progesterone group compared with placebo group (Table 1). 
This trial suggests that determination of cervical length is a 
powerful method for PTB risk assessment. However, until 
further trials, routine screening of low risk pregnant women 
by transvaginal ultrasound of cervical length is still not rec-
ommended, because only 1.7% (413/24,620) of the patients 
screened have short cervix in the mid trimester.108
There are 2 published observational data regarding the use 
of 17 OHP-C in the prevention of recurrent PTB. Rebarber 
et al109 in a retrospective analysis of data from 481 women 
who were enrolled for outpatient weekly IM 17OHP-C 
administrations. They found that women with elective early 
cessation of weekly 17OHP-C at  32 weeks’ gestation were 
signiﬁ  cantly more likely to have spontaneous recurrent PTD 
at  37 weeks,  35 weeks and  32 weeks of gestation when 
compared to the women who received weekly 17OHP-C 
injections until PTD or 36.9 weeks (Table 2). Discontinuation 
of 17OHP-C was deﬁ  ned as being elective when it occurred 
for any reason other than hospitalization for eminent delivery 
or an acute condition that led to delivery within 10 days. In 
this study, whether the elective discontinuation was patient 
or physician driven is not available from the database.
We performed a retrospectively analysis of database of 
women enrolled for outpatient 17OHP-C prophylaxis for 
prevention of spontaneous PTB.110 The data were divided 
into three groups according to the number of PTD (1, 2,  2) 
and stratiﬁ  ed to initiation of 17OHP-C at 16–20.9 weeks and 
21–26.9 weeks. We found that the rates of spontaneous PTB 
Table 2 Observational studies analyzing rates of preterm delivery (PTD) (%) according to when 17 OHP-C was discontinued, gestational 
age at initiation and number of previous PTD
Preterm labor Rebarber et al (2007)109 How et al (2007)110
Continued till 
36 wks n = 400a
Discontinued 
@   32 wks n = 81
Early initiation 
(16–20.9 wks)
N = 599
Late initiation 
(21–26.9 wks) 
N = 307
 37 wks (%) 33 48 Overall
1 PTD
2 PTD
 2 PTD
33
27
44b
59b
36
34
39
39
 35 wks (%) 14 31 Overall
1 PTD
2 PTD
 2 PTD
13
9
23b
20b
14
11
15
30b
 32 wks (%) 7 16 Overall
1 PTD
2 PTD
 2 PTD
5
4
9
7
4
2
2
18c
aPTD rates all signiﬁ  cantly different.
bp   0.05 vs 1 PTD group.
cp   0.05 vs 1 PTD and 2 PTD groups.Therapeutics and Clinical Risk Management 2009:5 61
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were signiﬁ  cantly higher in those with   2 PTD (n = 159, 
51% vs 27% at  37 weeks and 21% vs 9% at  35 weeks 
in the 17OHP-C start at 16–20.9 weeks group; 18% vs 2% 
at  32 weeks in the 17 OHP-C start at 21–26.9 weeks group) 
as compared to those with one PTD (n = 440) (Table 2). 
There were no signiﬁ  cant differences in spontaneous PTD 
rates according to the time of initiation of 17OHP-C at 
16–20.9 weeks vs 21–26.9 weeks GA (Table 2). We concluded 
that women with history of  2 PTD have a high risk of 
recurrent spontaneous PTD at  37 and  35 weeks despite 
17OHP-C prophylaxis. Later second trimester initiation of 
17OHP-C prophylaxis is as effective as initiation in the early 
second trimester. However, these conclusions should be 
interpreted with caution because data such as baseline cervical 
length, the GA or circumstances of the prior PTB, maternal 
race, and complete neonatal outcomes were not available.
Safety and tolerability
Synthetic progestins, including 17OHP-C have been 
associated with a less desirable side-effect proﬁ  le than that 
of natural progesterone, including mood swings, headaches, 
bloating, abdominal pain, perineal pain, constipation, diarrhea, 
nausea, vomiting, joint pain, depression, decreased sex drive, 
difﬁ  cult or painful intercourse, nervousness, sleepiness, breast 
enlargement, breast pain, nucturia, dysuria, polyuria, urinary 
tract infection, allergy, tiredness, dizziness, genital itching, 
yeast infection, vaginal discharge, fever, ﬂ  u-like symptoms, 
back pain, leg pain, sleep disorder, inﬂ  ammation of a sinus, 
upper respiratory infection, asthma, acne and pruritus. In 
the Meis trial,104 the most common undesirable side effect 
was injection site pain (35%), injection site swelling (17%), 
urticaria (12%), pruritus (8%), injection site pruritus (6%), 
nausea (6%), contusion (6%), injection site nodule (4%), and 
vomiting (3%).111
Meis et al104 and Heinonen et al112 reported a small, 
statistically non-signiﬁ  cant increased in miscarriage and 
stillbirths in women receiving progesterone. Our retrospectively 
study110 showed infrequent spontaneous abortion at  24 
weeks’ gestation (0.9%), stillbirth (0.5%), and neonatal 
death (0.4%) in women receiving progesterone prophylaxis 
to prevent PTB. Further investigation is necessary to evaluate 
the validity of these concerns.
Data from animal studies, suggest that increased plasma 
levels of progesterone may inﬂ  uence fetal behavior and 
induce fetal arousal states.113,114 There are no human data 
regarding long term outcome of women and infants who 
were exposed to progesterone in-utero until the most 
recent article published by NICHD trial115 reporting the 
4 year follow up of children exposed to 17OHP-C in utero. 
The children were 30–64 months of age at the time of 
the follow-up assessments. Of the 348 eligible surviving 
children, 278 (80%) were available for evaluation (194 
17OHP-C, 84 placebo). No signiﬁ  cant differences were 
seen in health status and conditions, or physical exam, 
including genital anomalies between 17OHP-C and placebo 
children. Developmental screen including communication, 
gross motor, ﬁ  ne motor, problem solving, personal-social 
issues were not signiﬁ  cantly different between 17OHP-C 
and placebo group. There are some concerns regarding the 
vehicle, castor oil, used in IM 17OHP-C. The castor oil is 
thought to induce labor by stimulating the release of prosta-
glandins, which might negate the potential beneﬁ  cial effect 
of IM 17-OHP-C.116
Patient focused perspectives such 
as quality of life, patient satisfaction/ 
acceptability
Weekly IM injections of 17 OHP-C may be undesirable 
to a portion of the population at risk for preterm delivery. 
Progesterone administered intramuscularly has been 
associated with several systemic and local skin complications. 
Some women may ﬁ  nd transvaginal delivery to be more 
acceptable than injection, but others may not agree. 
Suppositories can be difﬁ  cult to place high in the vagina 
and may liquefy, potentially leads to vaginal discharge, 
irritation, and infection. Vaginal cream and gel, which do 
not liquefy and are easier to apply, may alleviate some of 
the problems associated with transvaginal suppositories. 
Comparative data on the various methods of administration 
are thus needed to determine pharmacokinetic or tolerability 
differences, however, before one method can be recom-
mended over the others.
Conclusions, place in therapy
We believe that there is a place for progesterone in the 
prevention of PTB. However the optimal dosage, route and 
timely delivery of the drug remain controversial.
Direct comparison of different progesterone formulations 
and routes of administration is required to identify any 
preferences in pharmacokinetic behavior or tolerability 
issues. As stated by the ACOG committee, progesterone has 
only been studied as a “prophylactic measure in asymptomatic 
women” and therefore until further studies evaluate the use 
of progesterone in women with other high-risk obstetric 
factors “it is important to restrict its use to only women with 
a documented history of a previous spontaneous PTB. .…”117 Therapeutics and Clinical Risk Management 2009:5 62
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At present, it is prudent to await the result of several large 
clinical trials. (http://content.nejm.org/egi/date/357/5/499/
DCI/1) and basic science studies supported by NICHD, March 
of Dimes and others to provide additional evidence-based 
information in the near future to expand the recommended 
eligibility criteria for progesterone administration. In 
addition, more data are needed to ensure the safety of the 
mother and child exposed to any of these drugs.
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